Literature DB >> 17694505

Pramlintide reduced markers of oxidative stress in the postprandial period in patients with type 2 diabetes.

Antonio Ceriello1, Cameron W Lush, Tamara Darsow, Ludovica Piconi, Maddelena Corgnali, Nuwan Nanayakkara, Juan P Frias, David Maggs.   

Abstract

BACKGROUND: The production of oxidative stress as a result of postprandial hyperglycaemia is now recognized as an important contributing factor in the development of diabetes complications. The objective of this study was to examine the effects of pramlintide on plasma concentrations of glucose and several markers of oxidative stress in patients with type 2 diabetes following a standardized meal.
METHODS: This was a randomized, single-blind, placebo-controlled, crossover study conducted at two clinical research centres in the United States. A total of 19 subjects (9 men and 10 women) with type 2 diabetes using mealtime insulin participated in the study. Pramlintide (120 microg), or placebo, and rapid-acting mealtime insulin were administered prior to a standardized meal on two separate study days. Plasma concentrations of glucose, nitrotyrosine (NT), oxidized-LDL cholesterol (OxLDL-C), and total radical trapping parameter (TRAP) were assessed during the 4-h postprandial period.
RESULTS: Compared to placebo, pramlintide treatment reduced postprandial excursions of glucose, NT, and OxLDL-C and protected TRAP from consumption. Correlation analysis revealed positive associations between placebo-corrected glucose incremental AUC(0-4 h) and both NT and OxLDL-C and a negative association between placebo-corrected glucose incremental AUC(0-4h) and TRAP.
CONCLUSIONS: The reduction in postprandial glucose excursions achieved with addition of pramlintide to rapid-acting insulin in type 2 diabetes was associated with a reduction in postprandial markers of oxidative stress. Copyright (c) 2007 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 17694505     DOI: 10.1002/dmrr.765

Source DB:  PubMed          Journal:  Diabetes Metab Res Rev        ISSN: 1520-7552            Impact factor:   4.876


  6 in total

Review 1.  Management of type 2 diabetes: evolving strategies for the treatment of patients with type 2 diabetes.

Authors:  Ebenezer A Nyenwe; Terri W Jerkins; Guillermo E Umpierrez; Abbas E Kitabchi
Journal:  Metabolism       Date:  2011-01       Impact factor: 8.694

2.  Characterization of cardiovascular outcomes in a type 2 diabetes glucose supply and insulin demand model.

Authors:  Scott V Monte; Jerome J Schentag; Martin H Adelman; Joseph A Paladino
Journal:  J Diabetes Sci Technol       Date:  2010-03-01

3.  Neuroprotective Effects of the Amylin Analog, Pramlintide, on Alzheimer's Disease Are Associated with Oxidative Stress Regulation Mechanisms.

Authors:  Sarah Patrick; Rachel Corrigan; John Grizzanti; Megan Mey; Jeff Blair; Merce Pallas; Antonio Camins; Hyoung-Gon Lee; Gemma Casadesus
Journal:  J Alzheimers Dis       Date:  2019       Impact factor: 4.472

Review 4.  Update on the treatment of type 2 diabetes mellitus.

Authors:  Juan José Marín-Peñalver; Iciar Martín-Timón; Cristina Sevillano-Collantes; Francisco Javier Del Cañizo-Gómez
Journal:  World J Diabetes       Date:  2016-09-15

5.  Nitrosylated proteins in monocytes as a new marker of oxidative-nitrosative stress in diabetic subjects with macroangiopathy.

Authors:  U Julius; V R Drel; J Grässler; I G Obrosova
Journal:  Exp Clin Endocrinol Diabetes       Date:  2008-08-25       Impact factor: 2.949

6.  Pramlintide: An Amylin Analogue Protects Endothelial Cells against Oxidative Stress through Regulating Oxidative Markers and NF-κb Expression.

Authors:  Leila Safaeian; Fatemeh Shafiee; Marzieh Naderi
Journal:  Int J Prev Med       Date:  2022-02-08
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.